Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Articles|October 18, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
Emerging Therapies for the Treatment of Mantle Cell Lymphoma
Author(s)Ari M. Melnick, MD
Ari M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.
Advertisement
Ari M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.
Articles in this issue
about 13 years ago
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myelomaabout 13 years ago
Clinical Advances in Mantle Cell Lymphomaabout 13 years ago
In Brief: Phase III Trials in Multiple Myelomaabout 13 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?about 13 years ago
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemiaabout 13 years ago
Transforming Expectations and Outcomes With Targeted Therapiesabout 13 years ago
The Utility of Pomalidomide in R/R Multiple Myelomaabout 13 years ago
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHLAdvertisement
Related to this article
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5